{"name":"Simcere Pharmaceutical","slug":"simcere","ticker":"2096.HK","exchange":"HKEX","domain":"simcere.com","description":"Simcere Pharmaceutical Group or Simcere Pharmaceutical is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. Its focus is to introduce generic and pharmaceutical products for the treatment of diseases with high incidence and/or mortality rate. The company has introduced a generic anti-stroke medication under the brand name, Bicun, and an anti-cancer medication under the brand name, Endu. Its products include antibiotics, anti-stroke medications, anti-inflammatory drugs, anti-cancer medications and other medicines. In addition, it has obtained approvals from the China State Food and Drug Administration (SFDA) to manufacture and sell over 210 other products.","hq":"Nanjing, China","founded":2000,"employees":"7038","ceo":"Jinsheng Ren","sector":"Oncology / CNS / Autoimmune","stockPrice":13.73,"stockChange":0.11,"stockChangePercent":0.81,"marketCap":"$35.5B","metrics":{"revenue":7731410944,"revenueGrowth":17.7,"grossMargin":81.6,"rdSpend":0,"netIncome":1344007936,"cash":3577615872,"dividendYield":1.5,"peRatio":22.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Simtuzumab patent cliff ($1.2B at risk)","drug":"Simtuzumab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Edaravone dexborneol sublingual tablet","genericName":"Edaravone dexborneol sublingual tablet","slug":"edaravone-dexborneol-sublingual-tablet","indication":"Other","status":"phase_2"},{"name":"SIM0916","genericName":"SIM0916","slug":"sim0916","indication":"Other","status":"phase_3"},{"name":"Edaravone Dexborneol Sequential Therapy","genericName":"Edaravone Dexborneol Sequential Therapy","slug":"edaravone-dexborneol-sequential-therapy","indication":"Acute ischemic stroke","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SIM0718 Injection","genericName":"SIM0718 Injection","slug":"sim0718-injection","indication":"Chronic hepatitis B","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Gemcitabine-Cisplatin chemotherapy","genericName":"Gemcitabine-Cisplatin chemotherapy","slug":"gemcitabine-cisplatin-chemotherapy","indication":"Non-small cell lung cancer","status":"marketed"}]}],"pipeline":[{"name":"SIM0718 Injection","genericName":"SIM0718 Injection","slug":"sim0718-injection","phase":"phase_3","mechanism":"SIM0718 is a recombinant human serum albumin-interferon alpha fusion protein that enhances antiviral and immunomodulatory responses.","indications":["Chronic hepatitis B","Chronic hepatitis C"],"catalyst":""},{"name":"Edaravone dexborneol sublingual tablet","genericName":"Edaravone dexborneol sublingual tablet","slug":"edaravone-dexborneol-sublingual-tablet","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SIM0916","genericName":"SIM0916","slug":"sim0916","phase":"phase_3","mechanism":"SIM0916 is a small molecule inhibitor that targets a specific molecular pathway involved in disease pathogenesis, though the exact mechanism requires further clarification.","indications":[],"catalyst":""},{"name":"Edaravone Dexborneol Sequential Therapy","genericName":"Edaravone Dexborneol Sequential Therapy","slug":"edaravone-dexborneol-sequential-therapy","phase":"phase_3","mechanism":"Edaravone reduces oxidative stress and neuroinflammation while dexborneol enhances cerebral blood flow and neuroprotection in a sequential combination therapy.","indications":["Acute ischemic stroke"],"catalyst":""},{"name":"Gemcitabine-Cisplatin chemotherapy","genericName":"Gemcitabine-Cisplatin chemotherapy","slug":"gemcitabine-cisplatin-chemotherapy","phase":"marketed","mechanism":"Gemcitabine and cisplatin work synergistically to damage cancer cell DNA and prevent its repair, leading to cell death.","indications":["Non-small cell lung cancer","Ovarian cancer","Bladder cancer","Pancreatic cancer","Breast cancer"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Simcere Pharmaceutical Reports 2023 Full-Year Results","summary":"The company reported a revenue increase of 15% year-over-year, driven by strong sales of its oncology products.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Simcere Pharmaceutical Partners with Chinese Biotech Firm to Develop New Cancer Therapies","summary":"The partnership aims to leverage the strengths of both companies to accelerate the development of novel cancer treatments.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"regulatory","headline":"Simcere Pharmaceutical Receives Approval for Simtuzumab in China","summary":"The company's flagship product, Simtuzumab, has been approved for marketing in China, marking a significant milestone for the company.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQeUdTSlNIaERhRzdKdkJNSjJhc0RoUk4xVGt0TXlidTZZT0Z2UDdqVl9xZXZaZ1M5MkItdWFhNGlVSGt6ZkE1MlF5Umt6T1NHS1E4dDNqSHgyWFVLbksyVl9LR0xUMXhWOTNBUmJzWWRxcF9jdDFtUWVXVmdqSUxNZDgteEtaUFctRlhLMUtOQ1NBTllXdlBKZFFJMmRteDdoc01CbXpsN2R4NERRMHRqa0cybEtFaWNZb09FQk9lUDZMa2NzOGYtZGsyS0JLa3VMOHoycThRcHNtSWc4NGc0aUtqS0tvY0dtbURVSFVESlZRSE9kb1B3OWdB0gH_AUFVX3lxTE9abEpKVHl3aXRTM1BxbVZpTXhDam1tVmN1RUtRbE42Z1lwQjVNXzhhcUZjX0YyNDYzd1NBSEdhX3BUbGFuZFJESW9UZ1JNeklDVmVFclNrTWJLZEI3M3doal95ZW1nNS1IYVo4N2ZDUEtQSk1kck1idUNsYmQ0YS1ZNjNsTVhLTWpIaW9VOHk0cnlKcGplclRIa25qYVVZdnlxRDdpakEyeHA0ZU1KOE1feFNqWE4tQko5alBwNnh2cktqTXdjYmlsWHdXcXJZRWVROWk1dnNId1NDTTRPOVdhc25UM3ZXYnJLUjdHalZTZ1c2NU5LVW5xelNEZUlQWQ?oc=5","date":"2026-04-08","type":"earnings","source":"simplywall.st","summary":"Assessing Simcere Pharmaceutical Group (SEHK:2096) Valuation After Strong 2025 Earnings Report - simplywall.st","headline":"Assessing Simcere Pharmaceutical Group (SEHK:2096) Valuation After Strong 2025 Earnings Report","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPUFNRUmRfOXBrUVBqbVpnMkQ1SFhHSG1HSnRudlpNQUJiaFRrVnZEZUxXWmZvNXM2WEZFaGhBVE5IbUYxaVBKanZ0MlNPM0Q4ZFoxU3JHenJmQ01XWmVDOWtEN0s3LURkRVAxeDZfY25JNmxtMVN2RHRpUE44SWlyOURnVlZZb0prejFXMlpOZXJzOXR4ckp2dkdEUU40Qnd1eE9oclVyVjlid21HcDJBTENMRlpZenQyeW91eQ?oc=5","date":"2026-04-01","type":"regulatory","source":"Smartkarma","summary":"Simcere Pharma (2096 HK): Sturdy 2025; Promising Pipeline, Approvals Will Take It Forward - Smartkarma","headline":"Simcere Pharma (2096 HK): Sturdy 2025; Promising Pipeline, Approvals Will Take It Forward","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQYUhSRmcwTUpYT1IydDBiWmlvSGltTjZITXdYNFprUjFjMk9FbmJ4cGh1RVNLQ1BMZjExQU5iSTVtS1MzUm9URUpfc2JxT0hwcjIzdnJaZVZwck1mWkV0czhrRDZZRkFLbU9hWng0VjJkNDY4LTdENUpMRXp2eTZ6OEU2TTdRYzl4MFhQYXVXckRrLXdnSzFneDdKUlFJUzN4QWJQajlEVEZWZllTYUlFREs5VXFaSkRpN2RVUVFlU0hYN3FlcG41WTlNWFRFcEFKZXg0dmZXNzFneFpOb0traE8tR04yUXBwUjg5UDR1aUY1ZTc0ZzRSQThn0gH_AUFVX3lxTE9Lc1R1cmJHQlpjbkEzdExCZXhnT1FFSkszLTJya09XSEl2LUJyQkFHUmkyMXZuY0NtNDg2bFVDOGJEY3JjV2Z1YjRoWHRPSXIzR0ZGV2FmZXBoU2x4dVFEQjdQNUVrdWFkWV81QURBQi1WalFKYXdXbTJ5aUNuVVRkVk5YNlV6WVBramtDR3A2d0g2bEFncldfNmRDZWlyeXltT3RkcTY5Yk1ndjFFTUZZczhMSlpxbnp5b095M2c3b3JGRkRMck1oRG9ZMFhpenNhRzE3SmJtb1JMZkFXaVI1VUZ3QnpOMy1JVURaUDE5REpEM3NsMC0tclkwQ1llOA?oc=5","date":"2026-03-30","type":"trial","source":"simplywall.st","summary":"Assessing Simcere Pharmaceutical Group’s Valuation After Strong Earnings And Positive SIM0237 Cancer Trial Results - simplywall.st","headline":"Assessing Simcere Pharmaceutical Group’s Valuation After Strong Earnings And Positive SIM0237 Cancer Trial Results","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNNzFqVGR6eXVoOEtSZFByNlhCX0FVMVBhRmZTX1lQVnpmUUVCWjVFRHJieG12cUVNVlVWM0hXYTB6V3h1UkVid2lyZGVDNFZmd3pmTkRyeGZLU01XSkV3VDZTelBqOVVOMlBXV0FUTzhub0RUY0RrLUd4ai1JZG1xWVJYU2EtaWZ0MzB4MGJYalpJeFNiUW1lRnM4M2kxb1J1c1JqQ0s3NlRjODI3Sm5DYnJmV3k1U3BfYWFUaXNqYUxyeEgtNzdoMVJIc1M1UUhSVzZkUkpLWXM1bGVHY1FiN1FSRHRmaWVzN2lLNWh5Q3h1MldZZUxfbNIB_gFBVV95cUxPbktzSHk1cThOMFYtY29laWRKaVltOHJmejdFMTFJUnpRVVNpaVQ1THMxQk5wWEt4TlNOQ21wMDBvVTFYbHhhMzQ4dTVtal9XMmM2clVMSDluYVVDNnVnV2MtTFJvOUlVQkVtTHEyRWJHNlQwV1NRUndfRHMzREl2LTBQOG1aTmE3c2ZjYm4yRnJQdEhucGwydWZBVnpYWDRoczVJQVdmbUV1UW5xUURHRExkQ1ZFVFhMUFNqS1VZS19INVlnRlFmVHV4ZnRtNkF0RzBDcXdfZWdWUkljYmZYYmoydFF6UFlBMHdiYnhJazFJQTNERndvcXlkLUV3QQ?oc=5","date":"2026-03-29","type":"pipeline","source":"simplywall.st","summary":"Simcere Pharmaceutical Group Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st","headline":"Simcere Pharmaceutical Group Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9COGRSMFdsNlktcVBtRU1PdnRPT1RLQ0NidW9pbVRVZjFKNFpXdEFCREV0WEY1cU1tbkJTTmVpZ2dzSVhLVGU5R01RTkdPWGVKTU5JS1lPSHhwalM5bHlTbEpxdmtMMkVpMDQ3WWVHRHJndw?oc=5","date":"2026-02-26","type":"earnings","source":"thebambooworks.com","summary":"BRIEF: Simcere Pharma profit surges in 2025 - thebambooworks.com","headline":"BRIEF: Simcere Pharma profit surges in 2025","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxNNXZhOWZBV1o0b2ZBVHNqelB6Y240b1FfRG1mMmVUZjNmS0ZCajc1eU5vUkQxdXREOHlUUm9UN1NkWDBoaDRXTDcteVIxUUtwQmd2N3JtbFFsX3JnSXB1WFI1a2xrU0R1OWhfMUsxYkcyckgwejZyOS1hRlNGYUVBallVRWkyMkgtbGl0b2E3cTJtWklzWldoMGNmRENFek5lRTJWTU85a0VTMkdEVlBhQUd1QjdBeWJ2UGhPNU5ieGFaRy16WXp0Ry1xUjIwcXlsVFNPX094alZ5N0drZEJSc1gxenYxTUxWUDFSRHpYaw?oc=5","date":"2026-02-25","type":"earnings","source":"Minichart","summary":"Simcere Pharmaceutical Issues Profit Alert: FY2025 Revenue and Profit Expected to Surge on Innovative Pharma Growth 12 - Minichart","headline":"Simcere Pharmaceutical Issues Profit Alert: FY2025 Revenue and Profit Expected to Surge on Innovative Pharma Growth 12","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQVTBTa3VBQ2lscWl5RGZMSlZFODdvcThpdUoyZTRENXp5SFdIVGVXRm13VWQ3SThadFlMNnZheFJ4Q1Z1aFZoSlNNQ0p3bmNSMWZvMkZqaUVDOWI2aTdKVk82RzU1MFYyZFlETGVBNno4MjlQc0EydzlLUDczWGhpaHVLUjFFR2ZQMmFJVXlaMmpSY1lOd0tLbE5WYlQyZVZvcmh2U2JBcWNfRFNBdFdmR05lMVBfRk9KdmNOdUxya3ZhR3BQRWdORGk0NUhyand0QTdxSzVzZkF6d0MzcVZOajUwUQ?oc=5","date":"2023-12-12","type":"pipeline","source":"Hong Kong Science & Technology Parks Corporation ('HKSTP'","summary":"Simcere Pharma Opens Innovation Center in Hong Kong to Accelerate R&D | HKSTP - Hong Kong Science & Technology Parks Corporation ('HKSTP'","headline":"Simcere Pharma Opens Innovation Center in Hong Kong to Accelerate R&D | HKSTP - Hong Kong Science & Technology Parks Cor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQalZPMFAzTjBqa0Jua1VmbUE4LU43YnFXRVJIZHRxQTQ0cHBnUm9pVldGN2ZaVXUtNW5ZSy1UeVRneXVmMVR4djRnZkE1dkcwRkd0dndqN1VHdU1vRDNyTFdLUHVjLXcwc3R2U2tNS3d5SHdxclZQNE5Pd1N0UTJ2TWJjV00yemFIRUkwOEpwYw?oc=5","date":"2020-10-27","type":"pipeline","source":"hkex.com.hk","summary":"SIMCERE PHARMACEUTICAL GROUP LTD. (2096) - stock price, quote, history - hkex.com.hk","headline":"SIMCERE PHARMACEUTICAL GROUP LTD. (2096) - stock price, quote, history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9wRkowSVBEcXRDU3dnVU5QRDdnV2c2WnhxamZYOG05YkVIZUZnLTMtdmdyZDhfMUdpRjZlWVVDek5jQU9IMEgxRTlkSXc0TWxqX2NsdG5n?oc=5","date":"2017-05-30","type":"pipeline","source":"Yahoo Finance Australia","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) stock price, news, quote and history - Yahoo Finance Australia","headline":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Simtuzumab","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":5,"phaseCounts":{"phase_3":3,"phase_2":1,"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Hengrui Medicine","BeiGene","Innovent Biologics"],"therapeuticFocus":["Oncology","Central Nervous System (CNS)","Autoimmune"],"financials":null,"yahoo":{"currentPrice":13.73,"previousClose":13.62,"fiftyTwoWeekHigh":15.08,"fiftyTwoWeekLow":7.07,"fiftyTwoWeekRange":"7.07 - 15.08","fiftyDayAverage":12.07,"twoHundredDayAverage":12.5,"beta":0.8,"enterpriseValue":31920572416,"forwardPE":16.2,"priceToBook":3.23,"priceToSales":4.59,"enterpriseToRevenue":4.13,"enterpriseToEbitda":19.46,"pegRatio":0,"ebitda":1640283008,"ebitdaMargin":21.2,"freeCashflow":0,"operatingCashflow":0,"totalDebt":1186932992,"debtToEquity":12.6,"currentRatio":2.21,"returnOnAssets":6.8,"returnOnEquity":16.3,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":4,"targetMeanPrice":17.25,"targetHighPrice":21.43,"targetLowPrice":12.74,"dividendRate":0.21,"payoutRatio":0.3,"fiveYearAvgDividendYield":0,"exDividendDate":1781654400,"insiderHeldPercent":68.5,"institutionHeldPercent":11,"sharesOutstanding":2582872618,"floatShares":783790522,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":0.61,"epsForward":0.85,"revenuePerShare":3.12,"bookValue":4.25,"officers":[{"age":63,"name":"Mr. Jinsheng  Ren","title":"Co-Founder & Chairman"},{"age":55,"name":"Mr. Yushan  Wan","title":"CFO, Joint Company Secretary & Executive Director"},{"age":44,"name":"Mr. Renhong  Tang Ph.D.","title":"Executive Director"},{"age":42,"name":"Ms. Xi  Wang","title":"VP & Executive Director"},{"age":53,"name":"Dr. Yunshu  Zhou","title":"Chief Executive Officer"},{"age":46,"name":"Mr. Gaobo  Zhou","title":"Chief Investment Officer"},{"age":60,"name":"Mr. Quanfu  Feng","title":"Vice President of Marketing"},{"age":null,"name":"Dr. Tamas  Oravecz Ph.D.","title":"Senior VP & Chief Scientific Officer of Simcere Zaiming"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.simcere.com","phone":"86 25 8556 6666"}}